Previous 10 | Next 10 |
2023-08-16 11:12:46 ET Summary Sarepta Therapeutics shows strong Q2 revenue growth and progresses in DMD treatment despite net losses. The company's liquidity position is robust with a cash runway of approximately 33 months. Sarepta's advancements in DMD treatment and ongoing ...
2023-08-16 09:31:41 ET Summary There is an ongoing phase 3 study, known as HOPE-3, deploying the use of CAP-1002 for the treatment of patients with Duchenne Muscular Dystrophy; Interim analysis expected Q4 of 2023. A Type-B FDA meeting was held between the company and the FDA; Min...
2023-08-14 08:15:00 ET Summary This article provides a dashboard with industry metrics in healthcare, then focus on the Global X Genomics & Biotechnology ETF. Pharmaceuticals/biotechnology and healthcare providers have fair value and quality scores. Healthcare equipment is...
2023-08-07 14:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-08-02 21:57:09 ET Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Conference Call August 2, 2023, 04:30 PM ET Company Participants Francesca Nolan - IR Director Doug Ingram - President and CEO Louise Rodino-Klapac - EEVP, Chief Scientific Officer and Head...
2023-08-02 21:00:34 ET Image source: The Motley Fool. Sarepta Therapeutics (NASDAQ: SRPT) Q2 2023 Earnings Call Aug 02, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Sarepta Therapeutics (SRPT) Q2 2023 Earnings Ca...
– Following approval on June 22, the first patient received commercially reimbursed ELEVIDYS (delandistrogene moxeparvovec-rokl), earlier today – Total revenues, which consist of net product revenues and collaboration revenues, for the second quarter 2023 totaled $26...
2023-07-27 07:30:00 ET Since the beginning of 2023, equity markets have been experiencing what could be the start of a bull run. Buying shares of growth stocks is an excellent move for investors looking to ride this wave. And while there are plenty of options on the market, looking at the h...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2023 financial results after the Nasdaq Global Market closes on Wednesday, August 2, 2023. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to d...
2023-07-13 05:49:59 ET Summary Sarepta reported a $516.8M loss in Q1 2023 but saw increased revenues ($253.5M) and holds $1.9B in assets. FDA's narrower approval for Elevidys impacted the stock but could expand with a successful confirmatory trial. Despite challenges, SRPT con...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...
2024-07-08 12:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...